RxDoctor Payments DataLook up a doctor →

Marc Taormina, MD

Gastroenterology · Lees Summit, MONPI 1992788038

Payments from drug & device makers

$55,087in general payments, 2019–2025

Across 1,104 payments — averaging $49.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Celltrion USA Inc.$22K
  • E.r. Squibb & Sons, L.L.C.$12K
  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • plus $10K from 41 others

What the payments were for

  • Consulting fees$4,5908%
  • Speaking & faculty fees$11,32021%
  • Travel & lodging$18,15433%
  • Food & beverage$20,32937%
  • Education$6401%
  • Entertainment$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,087 in reported general payments places this provider in the 85th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$661,550
Medicare patients
740
Services billed
30,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid14$134,593
RinvoqUpadacitinib14$123,927
ShingrixVaricella-Zoster Ge/As01b/Pf524$108,678
Boostrix TdapDiphth,pertuss(Acell),tet Vac174$10,833
Colestipol Hcl112$10,772
Mesalamine17$5,945
ArexvyRsvpref3 Antigen/As01e/Pf19$5,677
Pantoprazole Sodium424$4,232
Budesonide EcBudesonide15$3,028
Opium Tincture11$2,301
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,916
Budesonide DrBudesonide18$1,882
Balsalazide Disodium14$1,841
HavrixHepatitis A Virus Vaccine/Pf19$1,727
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine49$1,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$744$134,59314 claims
AbbVieRinvoq$4,246$123,92714 claims
Braintree Laboratories, Inc.Sutab$26$1,91612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →